Showing results (1241-1250 of 1,302) with videos related to

Sort By:
Pageof 131
Genome Medicine|September 24, 2022
Intratumor heterogeneity and T cell exhaustion in primary CNS lymphomaMichael Heming, Svea Haessner, Jolien Wolbert, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 14, 2006
WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activityKaren L Marquis, Annmarie L Sabb, Sheree F Logue, et al.
The Journal of Small Animal Practice|September 3, 2015
Cardiovascular-renal axis disorders in the domestic dog and cat: a veterinary consensus statementJ L Pouchelon, C E Atkins, C Bussadori, et al.
BMC Bioinformatics|October 21, 2011
Mitochondrial genome sequence analysis: a custom bioinformatics pipeline substantially improves Affymetrix MitoChip v2.0 call rate and accuracyHongbo M Xie, Juan C Perin, Theodore G Schurr, et al.
Clinical Lung Cancer|February 26, 2026
Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR DatabaseDiana Kim, Sarah Blocker, Courtney C Cavalieri, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 9, 2012
Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacyErin Milner, Jason Sousa, Brandon Pybus, et al.
Neuropharmacology|July 21, 2009
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonistRobert H Ring, Lee E Schechter, Sarah K Leonard, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2026
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practiceSarah Blocker, Diana Kim, Courtney C Cavalieri, et al.
Nature Neuroscience|February 26, 2008
Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memoryFeng Liu, Mark Day, Luis C Muñiz, et al.
Journal of Medicinal Chemistry|August 23, 2011
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparumErin Milner, Sean Gardner, Jay Moon, et al.
Pageof 131